GLP-1 and WADA: Is Semaglutide Doping?

Thomas Prommer Hybrid Athlete & Technology Executive Follow on Strava

Published: March 27, 2026

Updated: April 9, 2026

Current WADA Status (2026)

Let me start with the facts. As of January 2026, GLP-1 receptor agonists — including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — are on WADA's Monitoring Program. They are not on the Prohibited List.

The Monitoring Program is WADA's way of gathering data on substances that are not yet banned but are being watched. WADA added GLP-1 receptor agonists to the monitoring program in 2024 following the explosion of prescriptions globally and growing discussion about weight-sensitive sports. Being on this list means:

• Athletes are not required to declare GLP-1 use
• No Therapeutic Use Exemption (TUE) is needed
• It is legal to use before, during, and after competition
• WADA is collecting prevalence data through anonymous sample analysis
• A substance can remain on the monitoring list for years before any decision is made

Historically, substances spend 2-5 years on the monitoring program before WADA decides to either ban them or remove them from monitoring. Meldonium, for example, was monitored from 2015 before being banned in 2016. Other substances have been monitored and never banned.

Why WADA Is Watching

WADA evaluates substances against three criteria for prohibition: performance enhancement, health risk, and spirit of sport. GLP-1 is being watched primarily for the first and third.

The performance-enhancing argument

In weight-sensitive endurance sports, reducing body mass while maintaining power output directly improves performance. A marathoner who loses 5kg without losing fitness runs faster — the physics is straightforward. GLP-1 medications make this weight loss significantly easier and more predictable than diet alone.

The argument: if the medication enables weight loss that translates to faster race times, it is performance-enhancing regardless of whether that was the primary intent. This is the same logic that governs diuretics (banned as masking agents and weight-loss aids) in weight-class sports.

The access inequality argument

Brand-name GLP-1 medications cost $800-1,400 per month without insurance. Even compounded versions run $200-400 monthly. This creates a two-tier system where athletes who can afford the medication have access to a tool that others do not. In elite sport, financial inequality is already a factor (equipment, coaching, altitude camps), but a prescription medication adds a pharmaceutical dimension.

The Counterargument

There are substantial arguments against banning GLP-1 in sport:

It is a legitimate medical treatment

GLP-1 receptor agonists are FDA-approved medications prescribed for obesity and type 2 diabetes. Many athletes — including age-group athletes — have legitimate medical indications. Banning a medication that treats a chronic disease raises serious ethical and legal questions about an athlete's right to healthcare.

Weight loss is not a prohibited method

Diet, intermittent fasting, low-carb protocols, and strategic dehydration all achieve weight loss. None are banned. Altitude tents simulate erythropoiesis — the same mechanism as EPO — and are legal. If the outcome (weight loss) is legal, banning one method while allowing others is inconsistent.

The medication does not directly enhance performance

Unlike EPO (which increases oxygen-carrying capacity) or anabolic steroids (which build muscle), GLP-1 does not directly improve any athletic metric. It reduces appetite and slows gastric emptying. The performance benefit is entirely indirect, mediated through body composition changes that could be achieved through other means.

The TUE system could handle it

If WADA were to ban GLP-1, athletes with legitimate prescriptions would apply for Therapeutic Use Exemptions. Given that obesity affects a significant portion of age-group athletes, the TUE administrative burden could be enormous — and denying a TUE for an FDA-approved treatment would face legal challenges.

The Age-Group Athlete Question

This is where I think the conversation gets most interesting, and most personal. The ethics of GLP-1 use are different for a 40-year-old age-grouper than for an Olympic athlete.

Professional athletes compete for livelihoods. Their performance is their product. The integrity of professional sport depends on a level playing field, and any pharmaceutical advantage undermines that integrity — even a legal one.

Age-group athletes compete for personal achievement. We are not taking prize money from others. We are not representing national federations. Most of us are competing against our own previous performances, our own aging bodies, and our own standards.

Does using a prescribed medication to reach a healthier body weight violate the spirit of age-group competition? I struggle to see how it does when the same competition allows:

• Carbon-plated super shoes (a measurable performance advantage)
• Caffeine in strategic doses (an ergogenic aid)
• Altitude training camps (economically gated performance enhancement)
• Professional coaching and nutrition plans (access-dependent advantages)
• Thyroid medication, TRT with a prescription, and other hormone therapies

None of these are banned. All provide competitive advantages. The line we draw is not about "natural versus assisted" — it is about what WADA and sport governing bodies have decided to prohibit. Currently, GLP-1 is not on that list.

Why I Am Transparent About It

You are reading it. This entire content cluster — the protocol details, the body composition numbers, the side effect timeline, the race data — is my transparency. I did not wait to be asked. I chose to document my GLP-1 use publicly, with real data, from the beginning.

The reason is straightforward: I believe athletes should be open about everything that affects their performance. Supplements, medications, training methods, recovery tools — all of it. If I am comfortable doing it, I should be comfortable saying it. Secrecy implies that something needs hiding. I am using a prescribed medication, tirzepatide (Mounjaro) at 2.5mg per week, under the supervision of my physician, to manage body weight alongside a high training load. There is nothing to hide.

There is a difference between privacy and secrecy. Privacy is not volunteering your medical history at the start line. Secrecy is actively concealing something you believe gives you an advantage. I chose to publish rather than stay quiet because GLP-1 use among age-group endurance athletes is far more common than public conversation suggests. The gap between private use and public discussion is wide, and that gap breeds misinformation. By putting my numbers out — 94.5kg to 90kg, body fat from 13.0% to 11.3%, FTP from 261W to 281W, waist circumference down 2cm, belly circumference down 3.5cm — I am giving other athletes something concrete to compare against rather than anonymous forum speculation.

I will address the strongest counterargument directly: "But you could not have lost the weight without it." Maybe. I have lost weight through caloric restriction before. What I could not do was sustain that restriction while training 12-15 hours per week for Ironman distances. The hunger from high-volume endurance training is physiological, not psychological. GLP-1 made a medically supervised weight management approach possible alongside that training load. That is a tool — no different in principle from a power meter, a coach, or a structured nutrition plan. It does not increase my power output. It does not improve oxygen delivery. It does not enhance my recovery. It helps me eat less. The performance benefit comes from the weight loss itself, which is the same benefit any athlete gets from any effective approach to body composition.

My commitment is specific: if WADA moves GLP-1 receptor agonists from the monitoring program to the prohibited list, I will stop using tirzepatide before competition periods and document that transition publicly, the same way I documented starting it. Following the rules is not optional, even when you disagree with them. And if a Therapeutic Use Exemption becomes required, I will apply for one through the proper channels. The rules may change. My willingness to comply will not.

What Other Sports Organizations Say

WADA sets the global framework, but individual federations can implement additional rules. Here is where the major endurance sports organizations stand as of 2026:

It is worth noting that anti-doping testing at the age-group level is extremely rare in most endurance sports. In practice, the regulatory framework affects professional athletes far more than recreational competitors. This does not change the ethical question, but it is part of the reality.

My Prediction: Where This Is Headed

I expect GLP-1 receptor agonists to remain on the WADA monitoring list through at least 2027. Here is my reasoning:

• The medical treatment argument is strong. Banning a widely prescribed medication for a common chronic disease (obesity) would be unprecedented and legally risky for WADA.
• Detection is complex. Semaglutide is a peptide hormone analog with a long half-life. Distinguishing therapeutic use from "performance" use is virtually impossible — the substance is the same either way.
• The TUE burden would be enormous. If banned, hundreds of thousands of age-group athletes worldwide would potentially need TUEs. The administrative system is not built for that scale.
• Weight-class sports are the real pressure point. If GLP-1 gets banned, it will be driven by combat sports and weight-class events (boxing, wrestling, judo), not endurance sports. The argument is much stronger when athletes use it to make weight for a specific class.

The more likely outcome, in my view, is that WADA develops specific guidelines — possibly requiring disclosure or TUE for competitive athletes while leaving age-group athletes unrestricted. But I have been wrong before, and the regulatory landscape can shift quickly.

Whatever WADA decides, I will comply. If GLP-1 is banned, I will stop using it before competition periods. If a TUE is required, I will apply for one. Following the rules is not optional — even when you disagree with them.

For my complete protocol, weight data, and performance outcomes, see my full GLP-1 journey. For the body composition data that informed my tirzepatide choice, see tirzepatide vs semaglutide for athletes.